Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company demonstrated strong revenue growth with total revenue of 38.15 billion RMB in 2H25, reflecting a year-on-year increase of 28.0%, surpassing the consensus estimate of 22.2% [1] - Non-IFRS net profit for 2H25 reached 2.96 billion RMB, up 37.9% year-on-year, with a non-IFRS net profit margin of 7.8%, an increase of 0.6 percentage points [1] - The company is expected to achieve a compound annual growth rate (CAGR) of 19.5% in revenue from 2025 to 2027, supported by enhanced operational capabilities in the pharmaceutical category [1][5] Revenue and Profitability - In 2H25, sales of pharmaceutical and health products amounted to 31.55 billion RMB, a year-on-year increase of 26.8%, indicating a recovery in growth rate compared to 1H25 [2] - The platform, advertising, and other service revenues reached 6.60 billion RMB, growing by 33.8% year-on-year, driven by a robust increase in user traffic [2] - The company plans to expand its offline business, having opened over 300 self-operated pharmacies by the end of 2025, significantly exceeding its initial target [3] AI and Technology Integration - The company has developed a product matrix in the AI medical field, including various AI tools for patient management and evidence-based medicine [4] - The AI doctor "Daiwei" has completed millions of interactions with a satisfaction rate of 98% [4] Financial Forecasts and Valuation - The report adjusts the non-IFRS net profit forecasts for 2026 and 2027 to 6.62 billion RMB and 7.75 billion RMB, respectively, reflecting a decrease due to interest income impacts and investments in O2O and AI [5][11] - The target price is set at 65.20 HKD, based on a 28.0x target non-IFRS PE valuation for 2026, which is a premium compared to the average PE of comparable companies [5][14]